Sign In
Buy GSK
$50.67
-1.48 (-2.84%)
At Close: Jun 18, 2026
GSK to buy 35Pharma for $950 million
02:18am, Wednesday, 25'th Feb 2026
GSK on Wednesday agreed to buy Canadian biopharmaceutical company 35Pharma Inc for $950 million in cash.
MONTREAL, Feb. 25, 2026 (GLOBE NEWSWIRE) -- 35Pharma, a Canada-based, private, clinical-stage biopharmaceutical company specialised in the development of novel protein-based therapeutics today announc
GSK Strikes $1 Billion China RNA Deal
11:43am, Tuesday, 24'th Feb 2026
GSK plc (GSK) is making a calculated bet on next generation gene silencing drugs, signing a licensing agreement worth up to $1 billion with China's Frontier Bio
Frontier Biotechnologies strikes up to $1 billion deal with GSK
06:21am, Tuesday, 24'th Feb 2026
Frontier Biotechnologies said on Tuesday it has struck a deal with GSK , granting the British drugmaker worldwide rights to develop two small interfering RNA therapies targeting kidney diseases in an
Bora Pharmaceuticals and GSK Sign $250M Five Year Global Manufacturing Contract
01:13pm, Monday, 23'rd Feb 2026
MISSISSAUGA, Ontario--(BUSINESS WIRE)--Bora Pharmaceuticals and GSK Sign $250M Five Year Global Manufacturing Contract.
GSK Sees Unusually High Options Volume (NYSE:GSK)
03:00am, Friday, 20'th Feb 2026
GSK PLC Sponsored ADR (NYSE: GSK - Get Free Report) was the recipient of unusually large options trading activity on Thursday. Stock traders purchased 81,873 call options on the stock. This represents
GSK (NYSE:GSK) Share Price Passes Above Two Hundred Day Moving Average – What’s Next?
04:16am, Thursday, 19'th Feb 2026
GSK PLC Sponsored ADR (NYSE: GSK - Get Free Report) passed above its two hundred day moving average during trading on Wednesday. The stock has a two hundred day moving average of $46.15 and traded as
PHILADELPHIA--(BUSINESS WIRE)--GSK's AREXVY associated with reductions in certain RSV-related risks, real world study shows.
GSK: Post-Pivot Buoyancy Set To Continue After Strong 2025 (Upgrade)
12:10pm, Tuesday, 17'th Feb 2026
GSK plc is a pharma worthy of a Buy rating, based on past performance and future prospects. In 2025, the company grew revenues by 7% and core EPS by 12%. GSK seems to have successfully pivoted into a
Mark Hillman's Strategic Move: Significant Addition to State Street SPDR S&P 500 ETF Trust
12:01pm, Tuesday, 17'th Feb 2026
Insight into Mark Hillman (Trades, Portfolio)'s Fourth Quarter 2025 Investment Moves Mark Hillman (Trades, Portfolio) recently submitted the 13F filing for the
Kahn Brothers Reduces Stake in Pfizer Inc by 21.66%
12:00pm, Thursday, 12'th Feb 2026
Insights from Kahn Brothers (Trades, Portfolio)' Fourth Quarter 2025 13F Filing Kahn Brothers (Trades, Portfolio) recently submitted their 13F filing for the f
Citi lifts GSK target price but keeps neutral stance after rally
07:26am, Monday, 09'th Feb 2026
Citi has raised its price target for GSK PLC (LSE:GSK, NYSE:GSK) to £22.50 while maintaining a 'neutral' rating, citing a sharp rally driven by improving investor sentiment. The broker said full-ye
Citi lifts GSK target price but keeps neutral stance after rally
07:03am, Monday, 09'th Feb 2026
Citi has raised its price target for GSK PLC (LSE:GSK, NYSE:GSK) to £22.50 while maintaining a 'neutral' rating, citing a sharp rally driven by improving...
GSK Gets EU Approval for Expanded Use of Nucala in COPD
12:46pm, Friday, 06'th Feb 2026
GSK secures EU approval for Nucala, an add-on maintenance treatment for chronic obstructive pulmonary disease in adults.
ShoreCap says GSK has cracked it and the £40bn prize is now in sight
05:20am, Friday, 06'th Feb 2026
Yesterday's results looked solid. Today Shore Capital goes further, arguing GSK has effectively delivered its medium-term plan a year early and that a £40 billion revenue ambition for 2031 is now cr
